Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis

Metastasis to the CNS has a very poor prognosis and limited therapeutic response because it is difficult for drugs to cross the blood-brain barrier. However, T-DXd has yielded positive results for BMs in clinical trials. Additionally, a therapeutic effect of T-DXd on ISCM and BMs was observed in the reported cases.

Authors

Institutions

Publication Details

Journal
Case Reports in Oncology
Published
2024-12-23
DOI
https://doi.org/10.1159/000542761
Citations
2
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis

Keiko Kajitani, Tomoko Itagaki, Hiroaki Yamane
2 citations
Case Reports in Oncology
HER2/EGFR in Cancer Research
0.57
article

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis

Keiko Kajitani, Tomoko Itagaki, Hiroaki Yamane
article en
2 citations

Abstract

Metastasis to the CNS has a very poor prognosis and limited therapeutic response because it is difficult for drugs to cross the blood-brain barrier. However, T-DXd has yielded positive results for BMs in clinical trials. Additionally, a therapeutic effect of T-DXd on ISCM and BMs was observed in the reported cases.

Case Reports in OncologyVol. 18(1)
Hiroshima General Hospital (JP)
Openalex Percentile: Top 26%
HER2/EGFR in Cancer Research
0.57
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis — Keiko Kajitani, Tomoko Itagaki, et al. · Case Reports in Oncology (2024) | TGRS Research Map | TGRS